Epigenetic combination therapy as a tumor‐selective treatment approach for hepatocellular carcinoma

Abstract

Because the combined HDAC-I/DA epigenetic approach was found to produce significant antitumor effects in HCC model systems and did not impair cellular integrity of untransformed hepatocytes, this combination therapy is now considered for further investigation in clinical trials.